Tamiflu’s 2019 full-year sales of USD 388 million were flat compared with 2018, its U.S. sales plummeted 75％ to merely USD 44.3 million.
The market size of influenza antiviral in China has doubled in recent years. The sales of Oseltamivir had surpassed RMB 6 billion in 2019 and is projected to exceed RMB 10 billion in 2020.
WHO downgraded oseltamivir on drug list in terms of less cost effectiveness in 2017.
In 2018, Baloxavir Marboxil for the treatment of influenza A and B launched in Japan and the US.